A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration
Clinical trial NCT02194166 · COMPLETED
Trial details
- NCT number
- NCT02194166
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-18
- Primary completion
- 2018-07-12
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.